Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 5/20 | 0.42 |
| ▸ | AQP1 | P29972 | 2/20 | 0.39 |
| ▸ | BRD4 | O60885 | 4/20 | 0.37 |
| ▸ | CREBBP | Q92793 | 4/20 | 0.37 |
| ▸ | PARP1 | P09874 | 3/20 | 0.37 |
| ▸ | MAOA | P21397 | 2/20 | 0.35 |
| ▸ | MAOB | P27338 | 2/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.35 |
| ▸ | CNR1 | P21554 | 1/20 | 0.35 |
| ▸ | CNR2 | P34972 | 1/20 | 0.35 |
| ▸ | EZH2 | Q15910 | 1/20 | 0.34 |
| ▸ | CYP2A13 | Q16696 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4596982 | 0.87 | AQP1 (0.50) | HTR1AAQP1BRD4CREBBPPARP1 | |
| SCHEMBL4767762 | 0.86 | AQP1 (0.51) | HTR1AAQP1BRD4CREBBPPARP1 | |
| SCHEMBL4595103 | 0.84 | NUDT1 (0.43) | HTR1AAQP1BRD4CREBBPPARP1 | |
| SCHEMBL4713782 | 0.83 | AQP1 (0.37) | AQP1ALOX15CNR2EZH2 | |
| SCHEMBL4714782 | 0.83 | MET (0.42) | HTR1AAQP1BRD4CREBBPPARP1 | |
| SCHEMBL4596995 | 0.82 | HTR1A (0.39) | HTR1AAQP1BRD4CREBBPPARP1 | |
| SCHEMBL4622437 | 0.81 | AQP1 (0.41) | HTR1AAQP1BRD4CREBBPPARP1 | |
| SCHEMBL4596590 | 0.81 | HTR1A (0.38) | HTR1AAQP1BRD4CREBBPPARP1 | |
| SCHEMBL4596855 | 0.81 | HTR2A (0.43) | HTR1AAQP1BRD4CREBBPPARP1 | |
| SCHEMBL4224615 | 0.80 | AQP1 (0.55) | AQP1EZH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1879569-A2 | THERAPEUTIC COMBINATIONS FOR THE TREATMENT OR PREVENTION OF PSYCHOTIC DISORDERS | Wyeth (US) | 2008-01-23 | — | — | EP | claimed |
| EP-1871355-A1 | NEW THERAPEUTIC COMBIANATIONS FOR THE TREATMENT OR PREVENTION OF DEPRESSION | Wyeth (US) | 2008-01-02 | — | — | EP | claimed |
| WO-2006116221-A2 | THERAPEUTIC COMBINATIONS FOR THE TREATMENT OR PREVENTION OF PSYCHOTIC DISORDERS | WYETH (US) | 2006-11-02 | — | — | WO | claimed |
| WO-2006116149-A1 | NEW THERAPEUTIC COMBIANATIONS FOR THE TREATMENT OR PREVENTION OF DEPRESSION | WYETH (US) | 2006-11-02 | — | — | WO | claimed |
| EP-1898895-A2 | TREATMENT OF DRUG ABUSE | Wyeth (US) | 2008-03-19 | — | — | EP | disclosed |
| EP-1874292-A2 | METHODS FOR MODULATING BLADDER FUNCTION | Wyeth (US) | 2008-01-09 | — | — | EP | disclosed |
| EP-1871356-A1 | DIHYDROBENZOFURAN DERIVATIVES AND USES THEREOF | Wyeth a Corporation of the State of Delaware (US) | 2008-01-02 | — | — | EP | disclosed |
| EP-1871355-A1 | NEW THERAPEUTIC COMBIANATIONS FOR THE TREATMENT OR PREVENTION OF DEPRESSION | Wyeth (US) | 2008-01-02 | — | — | EP | disclosed |
| EP-1871354-A1 | TREATMENT OF PAIN | Wyeth (US) | 2008-01-02 | — | — | EP | disclosed |
| WO-2006116148-A2 | (7-ARLYSUBSTITUTED 2, 3-DIHYDR0-1-BENZ0FURAN-2-YL) ALKYLAMINES IN THE TREATMENT' OF SUBSTANCE ABUSE | WYETH (US) | 2006-11-02 | — | — | WO | disclosed |
| WO-2006116170-A1 | DIHYDROBENZOFURAN DERIVATIVES AND USES THEREOF | WYETH (US) | 2006-11-02 | — | — | WO | disclosed |
| WO-2006116149-A1 | NEW THERAPEUTIC COMBIANATIONS FOR THE TREATMENT OR PREVENTION OF DEPRESSION | WYETH (US) | 2006-11-02 | — | — | WO | disclosed |
| WO-2006116169-A2 | METHODS FOR MODULATING BLADDER FUNCTION | WYETH (US) | 2006-11-02 | — | — | WO | disclosed |
| WO-2006116171-A1 | TREATMENT OF PAIN | WYETH (US) | 2006-11-02 | — | — | WO | disclosed |
| EP-1675840-A1 | DIHYDROBENZOFURANYL ALKANAMINE DERIVATIVES AS 5HT2C AGONISTS | Wyeth a Corporation of the State of Delaware (US) | 2006-07-05 | — | — | EP | disclosed |
| WO-2005044812-A1 | DIHYDROBENZOFURANYL ALKANAMINE DERIVATIVES AS 5HT2C AGONISTS | WYETH A CORPORATION OF THE STATE OF DELAWARE (US) | 2005-05-19 | — | — | WO | disclosed |